Reimbursed Care Access in Bermuda

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Government guidance on prohibited/imported goods and public information about controlled drugs lists illicit hallucinogens among banned substances and warns against importation. # #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Bermuda law enforcement and public reporting treat MDMA as an illicit recreational drug; recent police seizure reports and court cases underline active enforcement against importation and possession. # #.

There is no publicly available evidence of an on‑island, publicly reimbursed esketamine (Spravato) programme or broad private-clinic rollout in Bermuda as of current government and local media sources; esketamine is a regulated prescription medicine in jurisdictions where it is approved, but Bermuda’s public material stresses prohibition of importation of illicit drugs and does not list esketamine as an available reimbursed therapy. Clinically, ketamine (the racemate) is an internationally recognized anaesthetic and included on essential medicines lists, and any importation/medical use of specialised psychotropic formulations (including esketamine nasal spray) would require regulatory approval/import licences and appropriate clinical governance in Bermuda — none of which are publicly documented in Bermuda government guidance or local reporting. # #. Note: where esketamine is prescribed in other jurisdictions it is typically delivered at licenced clinics with specific documentation/monitoring and often subject to private insurance or special reimbursement rules; similar structures would be required locally but no Bermuda-specific reimbursement policy is publicly posted.

Ketamine is an established medical anaesthetic and analgesic used worldwide and is available for legitimate medical procedures; such mainstream medical uses are consistent with hospital practice globally. Bermuda’s hospital system provides surgical and acute care services where internationally standard anaesthetic agents (including ketamine where clinically indicated) are used under medical governance, but there is no public policy documentation showing a reimbursed, structured outpatient ketamine-for-depression programme or island‑wide reimbursement framework for psychiatric ketamine infusions. Any specialised psychiatric use would require local regulatory oversight, import licence and funder (public or private) agreements; public government pages emphasize that importation of controlled substances is tightly regulated. For the general medical status of ketamine as an essential medicine see WHO listings. # #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Bermuda’s customs and law‑enforcement guidance names hallucinogens among prohibited imports and prosecutions for importation/possession have occurred; there is no public documentation of legal medical or reimbursed programs involving DMT. #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. There is no Bermuda‑specific public policy or reimbursement pathway for 5‑MeO‑DMT; importation or possession would be treated under existing controlled‑substance enforcement. #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Bermuda has not published any licencing, medical framework, or reimbursement pathway for ibogaine treatment; any use would be unlawful except under expressly authorised research licences, which are not documented publicly. #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. The active constituent (DMT/related tryptamines) and preparations containing it fall under the same prohibitions as other hallucinogens; importation and possession are treated as illicit. Religious or traditional‑use exemptions are not documented in Bermuda public policy. #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Mescaline and mescaline‑containing extracts are treated as illicit; plant rules vary in different jurisdictions but Bermuda’s public guidance places hallucinogens and narcotics among prohibited imports without documented medicinal/reimbursed pathways. #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Designer phenethylamines (the 2C family and related synthetic psychedelics) are treated as illegal substances in Bermuda and have been cited in regional law‑enforcement reporting as emerging synthetic threats; no medical or reimbursement pathway exists. # #.